Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 11/20 | 0.55 |
| ▸ | HTR1D | P28221 | 7/20 | 0.55 |
| ▸ | HTR1B | P28222 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31185603 | 0.86 | HTR5A (0.55) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL5372246 | 0.86 | HTR5A (0.55) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL5371126 | 0.85 | MTNR1B (0.51) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL5373904 | 0.85 | BACE1 (0.51) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL6308917 | 0.85 | BACE1 (0.51) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL5375431 | 0.85 | BACE1 (0.51) | MTNR1BHTR1AHTR1DHTR1BMAPT | |
| SCHEMBL4558301 | 0.84 | BACE1 (0.59) | HTR1AHTR1DHTR1BALDH1A1CYP1A2 | |
| SCHEMBL5379402 | 0.84 | BACE1 (0.50) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL2176211 | 0.83 | MTNR1B (0.48) | MTNR1BALDH1A1MAPTSLC2A1BACE1 | |
| SCHEMBL4728868 | 0.83 | MAPT (0.52) | MTNR1BHTR1AHTR1DHTR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | MTNR1B 163/4885HTR1A 191/4885HTR1D 37/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MTNR1B 163/4885HTR1A 191/4885HTR1D 37/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MTNR1B 163/4885HTR1A 191/4885HTR1D 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.